Sunshine Guojian Pharmaceutical Co., Ltd. (688336)
SSE SSE Primary Summary
688336 Chart
People also search for
Sunshine Guojian Pharmaceutical Co., Ltd. (688336) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sunshine Guojian Pharmaceutical Co., Ltd. ever had a stock split?
Sunshine Guojian Pharmaceutical Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | SSE Exchange | CNE1000062X2 ISIN |
| CN Country | 965 Employees | 18 Jun 2026 Last Dividend | 18 Jun 2026 Last Split | - IPO Date |
Overview
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is a distinguished biopharmaceutical company rooted in China with a dedicated focus on the research, development, manufacturing, and commercialization of pioneering antibody drugs. Established in the year 2002 and having its base in Shanghai, China, the company strides forward in the biopharmaceutical domain, marking its prominence through the development of innovative therapeutic solutions. Sunshine Guojian is actively engaged in addressing the needs across a spectrum of medical fields including autoimmune diseases, tumors, and other significant diseases, showcasing its commitment towards enhancing healthcare and patient outcomes.
Products and Services
At the heart of Sunshine Guojian's mission is the development and commercialization of a range of specialized antibody drugs aimed at improving the quality of life for patients across various disease states. Each product in their portfolio represents a step forward in the fight against debilitating diseases.
- YISAIPU: A pivotal product in their lineup, YISAIPU is a tumor necrosis factor (TNF) inhibitor designed for the treatment of rheumatism. This therapeutic solution offers a beacon of hope for patients battling the chronic pain and inflammation associated with rheumatic diseases, improving their overall quality of life.
- Xenopax: As a recombinant humanized anti-CD25 monoclonal antibody injection, Xenopax carves a niche for itself by targeting and modulating immune responses. This product is central to Sunshine Guojian's endeavors in treating autoimmune diseases, among others, by harnessing the power of targeted antibody therapy.
- Cipterbin: Another cornerstone product, Cipterbin, stands out as an anti-HER2 monoclonal antibody. It plays a crucial role in the fight against certain types of cancers by specifically targeting the HER2 protein, a key player in the growth and development of cancer cells. Cipterbin's targeted approach exemplifies the company's forward-thinking in oncology.
